About NeuroDerm
NeuroDerm is a company based in Ness Ziona (Israel) founded in 2003 was acquired by Mitsubishi Tanabe Pharma in July 2017. NeuroDerm has raised $2.5 million across 6 funding rounds from investors including The Michael J. Fox Foundation and Mitsubishi Tanabe Pharma. NeuroDerm offers products and services including ND0612. NeuroDerm operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Ness Ziona, Israel
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website neuroderm.com
- Social LinkedIn X
- Acquired by Mitsubishi Tanabe Pharma (Jul 2017)
- Total Equity Funding$2.5M (USD)
in 6 rounds
- Latest Funding Round$1M (USD), Grant
Jun 2013
- InvestorsThe Michael J. Fox Foundation
& 1 more
- Acquired byMitsubishi Tanabe Pharma
(Jul 2017)
Products & Services of NeuroDerm
NeuroDerm offers a comprehensive portfolio of products and services, including ND0612.
Provides continuous subcutaneous treatment for Parkinson's motor fluctuations.
Funding Insights of NeuroDerm
NeuroDerm has successfully raised a total of $2.5M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $1 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.5M
- Total Rounds 6
- Last Round Grant — $1M
- First Round $490,000
(May 2006)
- Investors Count 1
All 6 funding rounds of NeuroDerm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2013 | $1M | Grant | – | – | |
| Oct 2010 | $1M | Grant | – | – | |
| Aug 2009 | $400,000 | Grant | – | – | – |
| Apr 2008 | $400,000 | Grant | – | – | – |
| Jul 2007 | $2.5M | Series A | – | – | – |
| May 2006 | $490,000 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in NeuroDerm
NeuroDerm has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include The Michael J. Fox Foundation and Mitsubishi Tanabe Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States | |
Innovative therapies and drugs are developed by the pharmaceutical company. | 1678 | mt-pharma.co.jp | Osaka, Japan |
Investor details for NeuroDerm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NeuroDerm
1 people are tracked at NeuroDerm (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ayelet Altman | CEO | Leadership |
Complete people profiles for NeuroDerm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NeuroDerm
5 dated milestones of NeuroDerm across 14 years, from founding to its latest funding, stage changes and deals.
- Founded NeuroDerm is founded.
- Funding First funding round of $490K.
- Funding Latest funding round, Grant, of $1.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Mitsubishi Tanabe Pharma.
Competitors of NeuroDerm
NeuroDerm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| lundbeck.com | 1915 | Copenhagen, Denmark | – | 393 | Drugs for CNS disorders are developed and advanced. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| karunatx.com | 2009 | Boston, United States | $132.1M | 339 | Therapies for psychosis and cognitive impairment are developed. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders |
Detailed competitors of NeuroDerm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NeuroDerm
The website of NeuroDerm (neuroderm.com) receives about 2.8K visits a month and ranks #5,643,423 among all websites worldwide, #6,184 in Biotechnology and Pharmaceuticals.
- Monthly visits2.8K
▼ 15.4% vs previous month
- Unique visitors1.4K
per month
- Global rank#5,643,423
among all websites
- Category rank#6,184
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.4
- Average visit2 sec
- DevicesDesktop 28% · Mobile 72%
Websites whose visitors overlap most with NeuroDerm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocentury.com | 100% | 85.7K | #514,907 | View details | |
| prothena.com | 94% | 5.6K | #3,145,374 | View details | |
iwanttoquitsmoking.com | iwanttoquitsmoking.com | 58% | – | #9,797,025 | – |
Latest news on Neuroderm
Complete news archive for NeuroDerm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to NeuroDerm
10 companies that operate in the same segment as NeuroDerm (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NeuroDerm
NeuroDerm was founded in 2003 and raised its 1st funding round 3 years after it was founded.
NeuroDerm is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Ayelet Altman is the current CEO of NeuroDerm.
NeuroDerm is a funded company, having raised a total of $2.5M across 6 funding rounds to date. The company's 1st funding round was a Grant of $490K, raised on May 2006.
NeuroDerm was founded in 2003 in Ness Ziona, Israel, and operates in the biotechnology sector focused on central nervous system disorders. A portfolio of levodopacarbidopa product candidates, including ND0612L for moderate cases, ND0612H for severe cases, and ND0680 for advanced stages, is developed using proprietary reformulation technology to provide continuous dosing. ND801 is also under development for cognitive disorders associated with Parkinsons disease.
NeuroDerm's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.
NeuroDerm offers ND0612.
NeuroDerm has 2 investors. Key investors include The Michael J. Fox Foundation, and Mitsubishi Tanabe Pharma.
Yes. NeuroDerm was acquired by Mitsubishi Tanabe Pharma in July 2017.